Comment on

• Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.

  Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Telfer P, et al. Haematologica. 2006 Sep;91(9):1187-92. Haematologica. 2006. PMID: 16956817
• Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.

  Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E. Voskaridou E, et al. Haematologica. 2006 Sep;91(9):1193-202. Haematologica. 2006. PMID: 16956818 Clinical Trial.
• A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.

  Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. Galanello R, et al. Haematologica. 2006 Sep;91(9):1241-3. Haematologica. 2006. PMID: 16956824 Clinical Trial.